10X Genomics Inc
NASDAQ:TXG
Intrinsic Value
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. [ Read More ]
The intrinsic value of one TXG stock under the Base Case scenario is 25.25 USD. Compared to the current market price of 26.51 USD, 10X Genomics Inc is Overvalued by 5%.
Valuation Backtest
10X Genomics Inc
Run backtest to discover the historical profit from buying and selling TXG stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
10X Genomics Inc
Current Assets | 596m |
Cash & Short-Term Investments | 388.7m |
Receivables | 114.8m |
Other Current Assets | 92.5m |
Non-Current Assets | 369.1m |
PP&E | 344.9m |
Intangibles | 21.1m |
Other Non-Current Assets | 3.1m |
Current Liabilities | 127.2m |
Accounts Payable | 15.7m |
Accrued Liabilities | 80.7m |
Other Current Liabilities | 30.7m |
Non-Current Liabilities | 96.9m |
Other Non-Current Liabilities | 96.9m |
Earnings Waterfall
10X Genomics Inc
Revenue
|
618.7m
USD
|
Cost of Revenue
|
-209.4m
USD
|
Gross Profit
|
409.3m
USD
|
Operating Expenses
|
-665.2m
USD
|
Operating Income
|
-255.9m
USD
|
Other Expenses
|
830k
USD
|
Net Income
|
-255.1m
USD
|
Free Cash Flow Analysis
10X Genomics Inc
TXG Profitability Score
Profitability Due Diligence
10X Genomics Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Score
10X Genomics Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
TXG Solvency Score
Solvency Due Diligence
10X Genomics Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Score
10X Genomics Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TXG Price Targets Summary
10X Genomics Inc
According to Wall Street analysts, the average 1-year price target for TXG is 56.61 USD with a low forecast of 30.3 USD and a high forecast of 73.5 USD.
Ownership
TXG Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
TXG Price
10X Genomics Inc
Average Annual Return | 26.92% |
Standard Deviation of Annual Returns | 79.64% |
Max Drawdown | -88% |
Market Capitalization | 3.2B USD |
Shares Outstanding | 119 170 000 |
Percentage of Shares Shorted | 10.16% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. The company is headquartered in Pleasanton, California and currently employs 1,239 full-time employees. The company went IPO on 2019-09-12. The firm's integrated solutions include instruments, consumables, and software for analyzing biological systems. Its products include Chromium Single Cell Gene Expression, Single Cell Immune Profiling, Single Cell assay for transposase accessible chromatin (ATAC) + Gene Expression, Single Cell ATAC, Spatial Gene Expression, Spatial Gene Expression, Spatial Multiomics, and Targeted Gene Expression. Its instruments include Chromium X Series, Chromium Connect, and Chromium Controller. Its technology Next GEM technology, which include chips and compatible reagents, which are offered for single cell product portfolio. Its consumables portfolio includes microfluidic chips, slides, reagents, and other consumables for both its Visium and Chromium solutions. The firm's applications include clustered regularly interspaced short palindromic repeats (CRISPR) screening, multiomic cytometry, and immune receptor mapping.
Contact
IPO
Employees
Officers
The intrinsic value of one TXG stock under the Base Case scenario is 25.25 USD.
Compared to the current market price of 26.51 USD, 10X Genomics Inc is Overvalued by 5%.